COMMERCIALIZATION AGREEMENTCommercialization Agreement • November 2nd, 2006 • Pharmacopeia Drug Discovery Inc • Services-commercial physical & biological research
This Amendment No. 1 (this “Amendment”), effective as of August 1, 2006 (the “Amendment Effective Date”), is entered into by and between SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a Pennsylvania corporation having a principal place of business at One Franklin Plaza, 200 N 16th Street, Philadelphia, PA 19102 (“SB Corp”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GGL”), SB Corp and GGL being collectively referred to hereinafter as “GSK”; and Pharmacopeia Drug Discovery, Inc., a Delaware corporation having a principal place of business at 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (“Pharmacopeia”). Pharmacopeia and GSK are each referred to herein by name or as a “Party” or, collectively, as the “Parties.” The Parties do hereby enter into this Amendment in order to amend that certain Product Development and C
AMENDMENT NO. 2Pharmacopeia Drug Discovery Inc • November 2nd, 2006 • Services-commercial physical & biological research
This Amendment No. 2 (this “Amendment No. 2”) to the Collaboration and License Agreements effective as of July 9, 2003 between (i) Pharmacopeia Drug Discovery, Inc. (f/k/a Pharmacopeia, Inc.) and Schering Corporation and (ii) Pharmacopeia Drug Discovery, Inc. and Schering-Plough Ltd. (collectively, as each has been amended by Amendment No. 1 dated July 27, 2006, the “2003 Agreements”), is effective as of September 22nd 2006 (the “Amendment No. 2 Effective Date”). By agreement of the Parties, as of the Amendment No. 2 Effective Date, this Amendment No. 2 amends the 2003 Agreements as follows:
